Last reviewed 2026-05-15 · How we verify

CoV-RBD-scNP-001 and 3M-052-AF

Duke University · Phase 1 active Biologic Quality 0/100

CoV-RBD-scNP-001 and 3M-052-AF is a Biologic drug developed by Duke University. It is currently in Phase 1 development.

At a glance

Generic name	CoV-RBD-scNP-001 and 3M-052-AF
Sponsor	Duke University
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Pancoronavirus Vaccine Study in Healthy Adults (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CoV-RBD-scNP-001 and 3M-052-AF CI brief — competitive landscape report
CoV-RBD-scNP-001 and 3M-052-AF updates RSS · CI watch RSS
Duke University portfolio CI

Frequently asked questions about CoV-RBD-scNP-001 and 3M-052-AF

What is CoV-RBD-scNP-001 and 3M-052-AF?

CoV-RBD-scNP-001 and 3M-052-AF is a Biologic drug developed by Duke University.

Who makes CoV-RBD-scNP-001 and 3M-052-AF?

CoV-RBD-scNP-001 and 3M-052-AF is developed by Duke University (see full Duke University pipeline at /company/duke-university).

What development phase is CoV-RBD-scNP-001 and 3M-052-AF in?

CoV-RBD-scNP-001 and 3M-052-AF is in Phase 1.

Manufacturer: Duke University — full pipeline